BG-12 filing data put pressure on Aubagio and Gilenya sales strategies
This article was originally published in Scrip
Detailed results from two pivotal clinical trials evaluating Biogen Idec's oral BG-12 (dimethyl fumarate) for the treatment of multiple sclerosis (MS) were published in the 20 September issue of the New England Journal of Medicine (NEJM).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.